Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A, Bonnet M, Rubinstein E, Pouget JP, Opolon P, Maigne L, Miot-Noirault E, Chezal JM, Boucheix C, Degoul F. Maisonial-Besset A, et al. Oncotarget. 2017 Mar 28;8(13):22034-22047. doi: 10.18632/oncotarget.15787. Oncotarget. 2017. PMID: 28423546 Free PMC article.
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A, Schmitt S, Briat A, Ty N, Maigne L, Quintana M, Membreno R, Zeglis BM, Navarro-Teulon I, Pouget JP, Chezal JM, Miot-Noirault E, Moreau E, Degoul F. Rondon A, et al. Among authors: navarro teulon i. Theranostics. 2019 Sep 19;9(22):6706-6718. doi: 10.7150/thno.35461. eCollection 2019. Theranostics. 2019. PMID: 31588245 Free PMC article.
General overview of radioimmunotherapy of solid tumors.
Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. Navarro-Teulon I, et al. Immunotherapy. 2013 May;5(5):467-87. doi: 10.2217/imt.13.34. Immunotherapy. 2013. PMID: 23638743 Review.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. Estupina P, et al. Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715. Oncotarget. 2017. PMID: 28427157 Free PMC article.
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Ashraf Y, et al. Among authors: navarro teulon i. J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z. J Immunother Cancer. 2019. PMID: 30717773 Free PMC article.
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M, Kashani R, Koch J, Sosabowski J, Foster J, Chouin N, Bruchertseifer F, Morgenstern A, Kotzki PO, Navarro-Teulon I, Pouget JP. Deshayes E, et al. Among authors: navarro teulon i. J Nucl Med. 2018 Aug;59(8):1234-1242. doi: 10.2967/jnumed.118.208611. Epub 2018 Apr 19. J Nucl Med. 2018. PMID: 29674421 Free article.
46 results